SDSamuel Diaz-Insa

Samuel Diaz-Insa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samuel Diaz-Insa has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recommendations on key aspects of migraine prevention: A Delphi consensus among experts of the headache study group of the Spanish society of neurology (GECSEN)

    by Sonia Santos-Lasaosa, Robert Belvís Nieto, Isabel Colomina, Samuel Díaz-Insa, Carmen González-Oria, Ángel Guerrero, Pablo Irimia, Julio Pascual, Patricia Pozo-Rosich, Jesús Porta-Etessam

    This study presents a Delphi consensus developed by the Headache Study Group of the Spanish Society of Neurology (GECSEN) to establish updated recommendations on key aspects of preventive migraine management. Given the high global burden of migraine and the emergence of novel preventive therapies—particularly OnabotulinumtoxinA and Calcitonin gene-related peptide (CGRP)-targeted treatments—there is a need to redefine therapeutic goals and optimize clinical decision-making. A nine-member Steering Committee defined 14 statements addressing five domains: candidate patient selection, therapeutic goals, treatment discontinuation, switching strategies, and combination therapy. A systematized literature review (171 selected publications) informed statement development. Eighty-eight migraine specialists participated in the first Delphi round and 48 in the second. Consensus was determined using the RAND/UCLA appropriateness method. Agreement was achieved for all 14 recommendations after two voting rounds. Preventive therapy is recommended in patients with ≥ 4 monthly migraine or moderate-to-severe headache days and relevant quality-of-life impairment. The ideal therapeutic goal is migraine freedom or minimization of attack frequency and intensity with improved quality of life. Optimal control is defined as < 4 monthly moderateto-severe headache days within three months. Treatment should generally be maintained for at least 12 months after achieving optimal control. Switching or combining preventive therapies—including CGRP monoclonal antibodies, gepants, and OnabotulinumtoxinA—may be considered in insufficient responders. This consensus proposes a treat-to-target strategy centered on patient-reported outcomes and residual disease burden, aiming to standardize preventive migraine care and improve long-term clinical outcomes.

  • Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine

    by Edoardo Caronna, Rut Mas-De-Les-Valls, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves-Castellanos, Leonardo Portocarrero, Gloria Vaghi, Joana Rodríguez-Montolio, Alex Jaimes, Albert Muñoz-Vendrell, et al.


  • Top Cited Papers

    Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine

    by Edoardo Caronna, Rut Mas-De-Les-Valls, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves-Castellanos, Leonardo Portocarrero-Sánchez, Gloria Vaghi, Joana Rodríguez-Montolio, Alex Jaimes, Albert Muñoz-Vendrell, et al.

    The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.


  • Open Access

    Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study

    by Samuel Díaz Insa, Ángel Guerrero, Javier Viguera, Vicente Medrano Martínez, Carlos Calle de Miguel, Jesús Porta-Etessam, Antonio Ciudad, Silvia Diaz-Cerezo, Ana Roncero Martín, Mercedes Núñez

    Introduction The efficacy of galcanezumab has been demonstrated in randomized controlled trials, but evidence about its use under clinical practice conditions is still limited. This study aimed to describe the characteristics of the patients treated with galcanezumab in routine clinical practice in Spain as well as treatment patterns, persistence, and effectiveness. Methods A retrospective chart review study was carried out in six hospitals. Information of adults with migraine, who started treatment with galcanezumab between November 2019 and September 2021, was analyzed until end or loss of follow-up. Continuous variables were described as mean (standard deviation, SD) and median (interquartile range, IQR), and categorical variables as frequency and percentages. Persistence to treatment was estimated using Kaplan–Meier analysis. Results A total of 314 patients were analyzed over median follow-up period of 17.5 months (13.8–20.7), with a mean age of 46.3 (12.6), 85% women, 80.6% chronic migraine, and reporting a mean of monthly migraine days of 16.7 (7.8). Overall, 72.9% had comorbid conditions, with anxiety and depression disorders being the most frequent. More than 60% had received ≥ 6 previous preventive drugs, the most common being antiepileptics, antidepressants, and botulinum toxin (95.2%, 89.8% and 84.1%, respectively). Overall, 60.3% of the patients with other preventive treatments maintained them after galcanezumab initiation. The median time on galcanezumab was 14.6 months (9.4–22.8); 95.7%, 82.0%, 76.2% and 59.8% of patients were persistent to treatment at 3, 6, 9 and 12 months, respectively. Of the patients who discontinued (151: 48.1%), 57.6% were due to lack of effectiveness and 31.1% were due to improvement in migraine. The average reduction of monthly migraine days at 3, 6, 9 and 12 months was 7.9 (7.2), 9.1 (7.5), 8.8 (6.6) and 9.0 (6.9) days, respectively. Conclusions In real clinical practice, galcanezumab is an effective treatment and has a high persistence in patients with migraine, mostly chronic and with multiple use of previous preventive treatments.


  • Open Access

    Burden of Episodic and Chronic Migraine in Patients Who Had Failed Multiple Preventive Treatments From France, Spain, and the United Kingdom

    by Samuel Díaz-Insa, Sonia Santos-Lasaosa, Maurice T. Driessen, Joshua M. Cohen, Lulu Lee, Peter J. Goadsby

    Objectives: Migraine affects more than 80 million people in Western Europe. The present study evaluated disability and health‐related quality of life (HRQoL) among patients with episodic migraine (EM) and chronic migraine (CM) who had failed multiple preventive treatments. Materials and Methods: This study was an analysis of cross‐sectional, web‐based survey data from adult patients with migraine (EM and CM) from the United Kingdom, France, and Spain who had self‐reported failure of two or more preventive treatments. Patient characteristics and patient‐reported HRQoL, migraine‐related disability, healthcare resource use (HCRU), and burden of migraine were evaluated by classification (CM and EM) and country (EM only). Results: In this sample of 316 patients (United Kingdom, n = 106; Spain, n = 105; France, n = 105), 76 (24.1%) patients had CM, the mean (standard deviation [SD]) age was 39.5 (12.3) years, and 164 (51.9%) patients were female. Those patients with CM reported greater migraine‐related disability based on Migraine Disability Assessment (MIDAS) scores versus those with EM (mean [SD]: 43.8 [44.7] vs. 23.2 [28.3]), as well as greater pain‐related impact on daily activities and higher HCRU. Among patients with EM, MIDAS scores indicated disability was severe in Spain (mean [SD]: 31.6 [31.1]) and France (24.3 [31.1]) and moderate in the United Kingdom (13.8 [17.9]), while HRQoL was similar across countries. Regarding the burden of EM, higher levels of pain and symptom‐related interference with many aspects of life, including occupational functioning, were reported in the United Kingdom and Spain versus France. Conclusions: Migraine is associated with substantial disability and decreased HRQoL among patients who have failed previous preventive therapies. Although migraine burden varied by country, the results suggest high unmet needs in all countries. Appropriate treatment could reduce migraine‐related burden and HCRU among patients with difficult‐to‐treat migraine.


  • Open Access

    Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders

    by Javier Pagonabarraga, Cecilio Álamo, Mar Castellanos, Samuel Díaz, Sagrario Manzano

    Depression and anxiety are highly prevalent in most neurological disorders and can have a major impact on the patient’s disability and quality of life. However, mostly due to the heterogeneity of symptoms and the complexity of the underlying comorbidities, depression can be difficult to diagnose, resulting in limited recognition and in undertreatment. The early detection and treatment of depression simultaneously with the neurological disorder is key to avoiding deterioration and further disability. Although the neurologist should be able to identify and treat depression initially, a neuropsychiatry team should be available for severe cases and those who are unresponsive to treatment. Neurologists should be also aware that in neurodegenerative diseases, such as Alzheimer’s or Parkinson’s, different depression symptoms could develop at different stages of the disease. The treatment options for depression in neurological diseases include drugs, cognitive-behavioral therapy, and somatic interventions, among others, but often, the evidence-based efficacy is limited and the results are highly variable. Here, we review recent research on the diagnosis and treatment of depression in the context of Alzheimer’s disease, Parkinson’s disease, and strokes, with the aim of identifying common approaches and solutions for its initial management by the neurologist.


  • Open Access

    Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START*study

    by M. Lanteri-Minet, S. Díaz-Insa, M. Leone, C. Vila, S. P. Clissold

    The benefits of taking almotriptan early for acute migraine when pain is mild have clearly been demonstrated in the neurology setting. The aim of this study was to determine whether similar benefits with early intervention of almotriptan can be achieved in everyday general practice, where most migraineurs are managed. In this European, prospective, observational study, patients were asked to treat up to three migraine attacks over a 2-month period with almotriptan 12.5 mg administered within 1 h of pain onset and when pain was mild (early + mild intervention group). A total of 501 patients were enrolled in primary care centres across Spain, France and Italy. The intention-to-treat analysis involved 454 patients who reported 1174 migraine attacks, with early intervention being used in 138 of these attacks. A greater proportion of patients who took almotriptan early + mild for their first migraine attack (n = 42) were pain free at 2 h compared with those in the non-early + mild intervention group (n = 410) (62% vs. 35%; p < 0.001). Similar results were obtained for all migraine attacks comparison [65% (n = 138) vs. 38% (n = 1036); p < 0.001]. Other secondary end-points were also significantly in favour of early + mild treatment, including sustained pain free (SPF), SPF with no adverse events (SNAE), and time lost because of migraine (all p < 0.001). Almotriptan was well tolerated with no serious adverse events reported. In the primary care setting, early intervention with almotriptan for treatment of migraine provides significant clinical benefits compared with delaying treatment and/or waiting until pain intensity has progressed beyond mild.